Associated Papers
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.
Sousa AC et al.
Lung Cancer (amsterdam, Netherlands), 2020
Effects of Single Nucleotide Polymorphisms on the Binding of Afatinib to EGFR: A Potential Patient Stratification Factor Revealed by Modeling Studies.
Kannan S et al.
Journal of Chemical Information and Modeling, 2019
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors.
Tsai MJ et al.
Cancers, 2018
Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket.
Kannan S et al.
Chemical Science, 2018
Clinical Analysis of Uncommon Epidermal Growth Factor Receptor Mutations in 16 Cases of Nonsmall Cell Lung Cancer.
Hu AM et al.
Chinese Medical Journal, 2018
Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.
Quan X et al.
Oncology Letters, 2018
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.
Kohsaka S et al.
Science Translational Medicine, 2017
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF et al.
The Oncologist, 2015
HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.
Boulbes DR et al.
Molecular Oncology, 2015
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y et al.
International Journal of Clinical and Experimental Pathology, 2013
Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma.
Enomoto Y et al.
Journal of Clinical Pathology, 2012
[Experience on epidermal growth factor receptor gene mutation analysis in non-small cell lung cancer].
Zhang J et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2011
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Kalikaki A et al.
British Journal of Cancer, 2008
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
Pallis AG et al.
British Journal of Cancer, 2007
NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy.
Kauffmann-Guerrero D et al.
Respiration; International Review of Thoracic Diseases, 0
Assessing Genetic Variants in Matched Biocompartments From Patients With Serous Ovarian Cancer.
Sanders BE et al.
Technology in Cancer Research & Treatment, 0